News

In the pivotal studies, Alecensa shrank tumors in up to 44 percent of people with ALK-positive NSCLC who progressed on crizotinib (objective response rate [ORR] of 38 percent

The proposed study, which will enroll approximately 75 patients, is projected to launch in Canada in Q2 2016. XBiotech medical director Michael Stecher said, "This program represents the

The candidate, CX-2009, is a first-in-class Probody drug conjugate targeting CD166. CX-2009 utilizes ImmunoGen, Inc. conjugate technology. CytomX chief scientific officer Michael Kavanaugh said: "CD166 is highly and

The collaboration aims to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome – research into

The Australian federal court ruled that Nurofen’s varieties for back pain, period pain, migraine pain and tension headaches were all found to feature the same active ingredient, 342

Patients with ALS fatal neurodegenerative disorder suffer progressive degeneration of the motor neurons, which leads to a declining quality of life and even could lead to death, the

Vistogard is claimed to be the first antidote for emergency treatment of 5-fluorouracil (5-FU) overdose treatment available to patients. It is also indicated for patients exhibiting early-onset, severe

The meeting with the FDA concerned the company’s cell-based product for the treatment of ALS. The response received on December 9, 2015 from the FDA represents a summary

"The ADAPT phase 3 trial to evaluate AGS-003 in front line mRCC, the largest global trial ever performed in newly diagnosed, unfavorable risk mRCC patients, continues to progress